Introduction: Glibenclamide may be an alternate treatment option for individuals with gestational diabetes mellitus in light of these findings and the fact that most pregnant women with the condition have relatively modest hyperglycemia. Therefore, the current study's goal was to assess the safety and effectiveness of glibenclamide versus insulin for treating gestational diabetes mellitus in the Indian population. Materials & Methods: The study included 500 female patients who visited the prenatal clinic in total. For the aim of the study, the patients were chosen at random. Indeed, the individuals who were included fell between the gestational age range of 10 to 35 weeks. According to the study's criteria, 70 out of the 500 patients had GDM. Ten of these patients were removed from the study because they did not provide consent to be part of it. Thirty of the sixty patients that remained received insulin therapy, and thirty received Glibenclamide tablets. The treatment regimen was followed, with these ladies being randomly assigned to receive either Glibenclamide or Insulin. Results: In both the insulin and glibenclamide groups, the proportion of pregnant women having a negative obstetric history and a positive family history of diabetes was nearly similar. Fasting plasma glucose greater than or equal to 95 mg/dl was present in 24 individuals in the insulin group and 4 participants in the glibenclamide group (fasting hyperglycemia). Random selection was used to treat the screened patients with either glibenclamide or insulin. Discussion & Conclusion: When treating GDM, glibenclamide may be a safe and effective substitute for insulin. The tiny sample size means that additional research is required to support this conclusion.